-
Je něco špatně v tomto záznamu ?
An insight into the complex roles of metallothioneins in malignant diseases with emphasis on (sub)isoforms/isoforms and epigenetics phenomena
S. Krizkova, M. Kepinska, G. Emri, T. Eckschlager, M. Stiborova, P. Pokorna, Z. Heger, V. Adam,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Grantová podpora
NV15-28334A
MZ0
CEP - Centrální evidence projektů
- MeSH
- epigeneze genetická MeSH
- lidé MeSH
- metalothionein metabolismus MeSH
- nádory farmakoterapie genetika metabolismus MeSH
- protein - isoformy MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Metallothioneins (MTs) belong to a group of small cysteine-rich proteins that are ubiquitous throughout all kingdoms. The main function of MTs is scavenging of free radicals and detoxification and homeostating of heavy metals. In humans, 16 genes localized on chromosome 16 have been identified to encode four MT isoforms labelled by numbers (MT-1-MT-4). MT-2, MT-3 and MT-4 proteins are encoded by a single gene. MT-1 comprises many (sub)isoforms. The known active MT-1 genes are MT-1A, -1B, -1E, -1F, -1G, -1H, -1M and -1X. The rest of the MT-1 genes (MT-1C, -1D, -1I, -1J and -1L) are pseudogenes. The expression and localization of individual MT (sub)isoforms and pseudogenes vary at intra-cellular level and in individual tissues. Changes in MT expression are associated with the process of carcinogenesis of various types of human malignancies, or with a more aggressive phenotype and therapeutic resistance. Hence, MT (sub)isoform profiling status could be utilized for diagnostics and therapy of tumour diseases. This review aims on a comprehensive summary of methods for analysis of MTs at (sub)isoforms levels, their expression in single tumour diseases and strategies how this knowledge can be utilized in anticancer therapy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19001160
- 003
- CZ-PrNML
- 005
- 20190115105355.0
- 007
- ta
- 008
- 190107s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.pharmthera.2017.10.004 $2 doi
- 035 __
- $a (PubMed)28987322
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Krizkova, Sona $u Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, CZ-616 00 Brno, Czech Republic; Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00 Brno, Czech Republic.
- 245 13
- $a An insight into the complex roles of metallothioneins in malignant diseases with emphasis on (sub)isoforms/isoforms and epigenetics phenomena / $c S. Krizkova, M. Kepinska, G. Emri, T. Eckschlager, M. Stiborova, P. Pokorna, Z. Heger, V. Adam,
- 520 9_
- $a Metallothioneins (MTs) belong to a group of small cysteine-rich proteins that are ubiquitous throughout all kingdoms. The main function of MTs is scavenging of free radicals and detoxification and homeostating of heavy metals. In humans, 16 genes localized on chromosome 16 have been identified to encode four MT isoforms labelled by numbers (MT-1-MT-4). MT-2, MT-3 and MT-4 proteins are encoded by a single gene. MT-1 comprises many (sub)isoforms. The known active MT-1 genes are MT-1A, -1B, -1E, -1F, -1G, -1H, -1M and -1X. The rest of the MT-1 genes (MT-1C, -1D, -1I, -1J and -1L) are pseudogenes. The expression and localization of individual MT (sub)isoforms and pseudogenes vary at intra-cellular level and in individual tissues. Changes in MT expression are associated with the process of carcinogenesis of various types of human malignancies, or with a more aggressive phenotype and therapeutic resistance. Hence, MT (sub)isoform profiling status could be utilized for diagnostics and therapy of tumour diseases. This review aims on a comprehensive summary of methods for analysis of MTs at (sub)isoforms levels, their expression in single tumour diseases and strategies how this knowledge can be utilized in anticancer therapy.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a epigeneze genetická $7 D044127
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a metalothionein $x metabolismus $7 D008668
- 650 _2
- $a nádory $x farmakoterapie $x genetika $x metabolismus $7 D009369
- 650 _2
- $a protein - isoformy $7 D020033
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kepinska, Marta $u Department of Biomedical and Environmental Analysis, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland.
- 700 1_
- $a Emri, Gabriella $u Department of Dermatology, Faculty of Medicine, University of Debrecen, Nagyerdei krt 98, H-4032 Debrecen, Hungary.
- 700 1_
- $a Eckschlager, Tomas $u Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, and University Hospital Motol, V Uvalu 84, CZ-150 06 Prague 5, Czech Republic.
- 700 1_
- $a Stiborova, Marie $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-128 40 Prague 2, Czech Republic.
- 700 1_
- $a Pokorna, Petra $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-128 40 Prague 2, Czech Republic; Department of Oncology, 2nd Faculty of Medicine, Charles University, and University Hospital Motol, V Uvalu 84, CZ-150 06 Prague 5, Czech Republic.
- 700 1_
- $a Heger, Zbynek $u Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, CZ-616 00 Brno, Czech Republic; Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00 Brno, Czech Republic.
- 700 1_
- $a Adam, Vojtech $u Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, CZ-616 00 Brno, Czech Republic; Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00 Brno, Czech Republic. Electronic address: vojtech.adam@mendelu.cz.
- 773 0_
- $w MED00006662 $t Pharmacology & therapeutics $x 1879-016X $g Roč. 183, č. - (2018), s. 90-117
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28987322 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190115105606 $b ABA008
- 999 __
- $a ok $b bmc $g 1365069 $s 1039283
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 183 $c - $d 90-117 $e 20171005 $i 1879-016X $m Pharmacology & therapeutics $n Pharmacol Ther $x MED00006662
- GRA __
- $a NV15-28334A $p MZ0
- LZP __
- $a Pubmed-20190107
